Ad is loading...
RDGL
Price
$0.10
Change
-$0.00 (-0.00%)
Updated
Nov 15 closing price
REMI
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 20 closing price
10 days until earnings call
Ad is loading...

RDGL vs REMI

Header iconRDGL vs REMI Comparison
Open Charts RDGL vs REMIBanner chart's image
Vivos
Price$0.10
Change-$0.00 (-0.00%)
Volume$1.75M
CapitalizationN/A
Remedent
Price$0.05
Change-$0.00 (-0.00%)
Volume$28K
CapitalizationN/A
RDGL vs REMI Comparison Chart
Loading...
RDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RDGL vs. REMI commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDGL is a Sell and REMI is a Hold.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (RDGL: $0.10 vs. REMI: $0.05)
Brand notoriety: RDGL and REMI are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: RDGL: 185% vs. REMI: 98%
Market capitalization -- RDGL: $23.83M vs. REMI: $3.4M
RDGL [@Medical Specialties] is valued at $23.83M. REMI’s [@Medical Specialties] market capitalization is $3.4M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RDGL’s FA Score shows that 0 FA rating(s) are green whileREMI’s FA Score has 0 green FA rating(s).

  • RDGL’s FA Score: 0 green, 5 red.
  • REMI’s FA Score: 0 green, 5 red.
According to our system of comparison, REMI is a better buy in the long-term than RDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RDGL’s TA Score shows that 3 TA indicator(s) are bullish.

  • RDGL’s TA Score: 3 bullish, 5 bearish.

Price Growth

RDGL (@Medical Specialties) experienced а -12.02% price change this week, while REMI (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.

Reported Earning Dates

RDGL is expected to report earnings on Mar 01, 2023.

REMI is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Medical Specialties (-4.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDGL($23.8M) has a higher market cap than REMI($3.4M). RDGL YTD gains are higher at: 35.201 vs. REMI (-48.454). REMI has higher annual earnings (EBITDA): -192.98K vs. RDGL (-1.97M). RDGL has more cash in the bank: 1.41M vs. REMI (83.3K). REMI has less debt than RDGL: REMI (5.46K) vs RDGL (295K). REMI has higher revenues than RDGL: REMI (1.13M) vs RDGL (29.5K).
RDGLREMIRDGL / REMI
Capitalization23.8M3.4M700%
EBITDA-1.97M-192.98K1,021%
Gain YTD35.201-48.454-73%
P/E RatioN/AN/A-
Revenue29.5K1.13M3%
Total Cash1.41M83.3K1,695%
Total Debt295K5.46K5,408%
FUNDAMENTALS RATINGS
RDGL vs REMI: Fundamental Ratings
RDGL
REMI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9889
PRICE GROWTH RATING
1..100
6478
P/E GROWTH RATING
1..100
8553
SEASONALITY SCORE
1..100
17n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REMI's Valuation (41) in the null industry is in the same range as RDGL (68). This means that REMI’s stock grew similarly to RDGL’s over the last 12 months.

RDGL's Profit vs Risk Rating (70) in the null industry is in the same range as REMI (100). This means that RDGL’s stock grew similarly to REMI’s over the last 12 months.

REMI's SMR Rating (89) in the null industry is in the same range as RDGL (98). This means that REMI’s stock grew similarly to RDGL’s over the last 12 months.

RDGL's Price Growth Rating (64) in the null industry is in the same range as REMI (78). This means that RDGL’s stock grew similarly to REMI’s over the last 12 months.

REMI's P/E Growth Rating (53) in the null industry is in the same range as RDGL (85). This means that REMI’s stock grew similarly to RDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RDGL
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
RDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SEGIX43.98-0.20
-0.45%
NAA Large Cap Value C
FTCEX11.59-0.08
-0.69%
Fidelity Advisor Total Intl Equity C
OGICX38.80-0.36
-0.92%
Invesco Global Opportunities C
USCGX14.32-0.15
-1.04%
Victory Capital Growth
SWTSX100.14-1.32
-1.30%
Schwab Total Stock Market Index

RDGL and

Correlation & Price change

A.I.dvisor tells us that RDGL and IART have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDGL and IART's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDGL
1D Price
Change %
RDGL100%
-6.90%
IART - RDGL
20%
Poorly correlated
-1.68%
RYLPF - RDGL
8%
Poorly correlated
N/A
SAFLY - RDGL
4%
Poorly correlated
N/A
POSC - RDGL
4%
Poorly correlated
-8.70%
REMI - RDGL
3%
Poorly correlated
N/A
More

REMI and

Correlation & Price change

A.I.dvisor tells us that REMI and AHICF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that REMI and AHICF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REMI
1D Price
Change %
REMI100%
N/A
AHICF - REMI
23%
Poorly correlated
N/A
SNANF - REMI
20%
Poorly correlated
N/A
SAFLY - REMI
7%
Poorly correlated
N/A
RDGL - REMI
3%
Poorly correlated
-6.90%
SAFLF - REMI
2%
Poorly correlated
N/A
More